国际妇产科学杂志 ›› 2021, Vol. 48 ›› Issue (4): 361-366.doi: 10.12280/gjfckx.20201063
• 产科生理及产科疾病 综述 • 下一篇
收稿日期:
2020-11-16
出版日期:
2021-08-15
发布日期:
2021-09-01
通讯作者:
曲洪美
E-mail:qhm791015@126.com
基金资助:
Received:
2020-11-16
Published:
2021-08-15
Online:
2021-09-01
Contact:
QU Hong-mei
E-mail:qhm791015@126.com
摘要:
妊娠期高血压疾病(hypertensive disorder complicating pregnancy,HDCP)是妊娠和高血压并存的一组疾病,是严重的妊娠期并发症,病因和发病机制目前尚未完全阐明。目前研究认为内在遗传因素与外在环境因素相互作用导致胎盘缺氧缺血是HDCP发病的主要机制。胎盘缺血缺氧促进生物活性因子释放到母体循环,一方面导致全身重要器官(脑、肾、肝)血管内皮增生、痉挛,从而引发高血压、蛋白尿、脑水肿和子痫等一系列的临床表现;另一方面生物活性因子抑制细胞外基质的降解,导致血管重塑能力不足,增加血管动脉硬化,血管阻力增加而加重胎盘缺血缺氧,引发HDCP循环往复。参与HDCP发病机制的生物活性因子主要有以下3种:抗血管生成因子、促血管生成因子和促炎性因子。结合近年来国内外文献,重点介绍3种活性因子在HDCP发病机制中的作用,为HDCP早期预测、早期诊断提供夯实的理论依据。
周文哲, 曲洪美. 生物活性因子在妊娠期高血压疾病发病机制中的作用[J]. 国际妇产科学杂志, 2021, 48(4): 361-366.
ZHOU Wen-zhe, QU Hong-mei. The Role of Biologically Active Factors in the Pathogenesis of Hypertension in Pregnancy[J]. Journal of International Obstetrics and Gynecology, 2021, 48(4): 361-366.
[1] |
Brown MA, Magee LA, Kenny LC, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice[J]. Pregnancy Hypertens, 2018, 13:291-310. doi: 10.1016/j.preghy.2018.05.004.
doi: S2210-7789(18)30126-0 pmid: 29803330 |
[2] |
中华医学会妇产科学分会妊娠期高血压疾病学组. 妊娠期高血压疾病诊治指南(2020)[J]. 中华妇产科杂志, 2020, 55(4):227-238. doi: 10.3760/cma.j.cn112141-20200114-00039.
doi: 10.3760/cma.j.cn112141-20200114-00039 |
[3] |
Uzan J, Carbonnel M, Piconne O, et al. Pre-eclampsia: pathophysiology, diagnosis, and management[J]. Vasc Health Risk Manag, 2011, 7:467-474. doi: 10.2147/VHRM.S20181.
doi: 10.2147/VHRM.S20181 |
[4] |
Podymow T, August P. Hypertension in pregnancy[J]. Adv Chronic Kidney Dis, 2007, 14(2):178-190. doi: 10.1053/j.ackd.2007.01.008.
doi: 10.1053/j.ackd.2007.01.008 |
[5] |
Keshavarzi F, Shahrakipoor M, Teimoori B, et al. Association of the placental VEGF promoter polymorphisms and VEGF mRNA expression with preeclampsia[J]. Clin Exp Hypertens, 2019, 41(3):274-279. doi: 10.1080/10641963.2018.1469644.
doi: 10.1080/10641963.2018.1469644 |
[6] |
Salimi S, Yaghmaei M, Tabatabaei E, et al. Vascular endothelial growth factor (VEGF)-634G/C polymorphism was associated with severe pre-eclampsia and lower serum VEGF level[J]. J Obstet Gynaecol Res, 2015, 41(12):1877-1883. doi: 10.1111/jog.12825.
doi: 10.1111/jog.12825 |
[7] |
Krauss T, Pauer HU, Augustin HG. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia[J]. Hypertens Pregnancy, 2004, 23(1):101-111. doi: 10.1081/PRG-120028286.
doi: 10.1081/PRG-120028286 |
[8] |
Ngene NC, Moodley J, Naicker T. The performance of pre-delivery serum concentrations of angiogenic factors in predicting postpartum antihypertensive drug therapy following abdominal delivery in severe preeclampsia and normotensive pregnancy[J]. PLoS One, 2019, 14(4):e0215807. doi: 10.1371/journal.pone.0215807.
doi: 10.1371/journal.pone.0215807 |
[9] |
Zhu M, Ren Z, Possomato-Vieira JS, et al. Restoring placental growth factor-soluble fms-like tyrosine kinase-1 balance reverses vascular hyper-reactivity and hypertension in pregnancy[J]. Am J Physiol Regul Integr Comp Physiol, 2016, 311(3):R505-R521. doi: 10.1152/ajpregu.00137.2016.
doi: 10.1152/ajpregu.00137.2016 |
[10] |
Mandalà M, Gokina N, Barron C, et al. Endothelial-derived hyperpolarization factor (EDHF) contributes to PlGF-induced dilation of mesenteric resistance arteries from pregnant rats[J]. J Vasc Res, 2012, 49(1):43-49. doi: 10.1159/000329821.
doi: 10.1159/000329821 |
[11] |
Palmer K. Assessing the Circulating Placental-Specific Anti-angiogenic Protein sFLT-1 e15a in Preeclampsia[J]. Methods Mol Biol, 2018, 1710:27-37. doi: 10.1007/978-1-4939-7498-6_3.
doi: 10.1007/978-1-4939-7498-6_3 |
[12] |
Zhu J, Zhang J, Ng MJ, et al. Angiogenic factors during pregnancy in Asian women with elevated blood pressure in early pregnancy and the risk of preeclampsia: a longitudinal cohort study[J]. BMJ Open, 2019, 9(11):e032237. doi: 10.1136/bmjopen-2019-032237.
doi: 10.1136/bmjopen-2019-032237 |
[13] |
Mitsui T, Tani K, Maki J, et al. Upregulation of Angiogenic Factors via Protein Kinase C and Hypoxia-induced Factor-1α Pathways under High-glucose Conditions in the Placenta[J]. Acta Med Okayama, 2018, 72(4):359-367. doi: 10.18926/AMO/56171.
doi: 10.18926/AMO/56171 |
[14] |
Saleh L, Tahitu S, Danser A, et al. The predictive value of the sFlt-1/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies[J]. Pregnancy Hypertens, 2018, 14:222-227. doi: 10.1016/j.preghy.2018.03.014.
doi: 10.1016/j.preghy.2018.03.014 |
[15] |
Han N, Li Y, Dong Y. Therapeutic Effect of Long-Term Epidural Block in Rats with Pregnancy Induced Hypertension[J]. Biomed Res Int, 2018, 2018:1639623. doi: 10.1155/2018/1639623.
doi: 10.1155/2018/1639623 |
[16] |
Morris R, Spencer SK, Barnes A, et al. Attenuation of oxidative stress and hypertension in an animal model of HELLP syndrome[J]. Eur J Pharmacol, 2018, 834:136-141. doi: 10.1016/j.ejphar.2018.07.013.
doi: 10.1016/j.ejphar.2018.07.013 |
[17] |
Zhao Y, Zheng Y, Liu X, et al. Inhibiting trophoblast PAR-1 overexpression suppresses sFlt-1-induced anti-angiogenesis and abnormal vascular remodeling: a possible therapeutic approach for preeclampsia[J]. Mol Hum Reprod, 2018, 24(3):158-169. doi: 10.1093/molehr/gax068.
doi: 10.1093/molehr/gax068 pmid: 29325127 |
[18] |
Rossi E, Bernabeu C, Smadja DM. Endoglin as an Adhesion Molecule in Mature and Progenitor Endothelial Cells: A Function Beyond TGF-β[J]. Front Med(Lausanne), 2019, 6:10. doi: 10.3389/fmed.2019.00010.
doi: 10.3389/fmed.2019.00010 |
[19] |
Umapathy A, Chamley LW, James JL. Reconciling the distinct roles of angiogenic/anti-angiogenic factors in the placenta and maternal circulation of normal and pathological pregnancies[J]. Angiogenesis, 2020, 23(2):105-117. doi: 10.1007/s10456-019-09694-w.
doi: 10.1007/s10456-019-09694-w |
[20] |
Leaños-Miranda A, Navarro-Romero CS, Sillas-Pardo LJ, et al. Soluble Endoglin As a Marker for Preeclampsia, Its Severity, and the Occurrence of Adverse Outcomes[J]. Hypertension, 2019, 74(4):991-997. doi: 10.1161/HYPERTENSIONAHA.119.13348.
doi: 10.1161/HYPERTENSIONAHA.119.13348 pmid: 31446801 |
[21] |
Bean C, Spencer SK, Pabbidi MR, et al. Peripheral Anti-Angiogenic Imbalance during Pregnancy Impairs Myogenic Tone and Increases Cerebral Edema in a Rodent Model of HELLP Syndrome[J]. Brain Sci, 2018, 8(12):216. doi: 10.3390/brainsci8120216.
doi: 10.3390/brainsci8120216 |
[22] |
徐振华, 王永红. 肿瘤坏死因子α调控MPO的分泌在子痫前期发病中的作用[J]. 国际妇产科学杂志, 2020, 47(1):64-67. doi: 10.3969/j.issn.1674-1870.2020.01.015.
doi: 10.3969/j.issn.1674-1870.2020.01.015 |
[23] |
Cunningham MW, Jayaram A, Deer E, et al. Tumor necrosis factor alpha (TNF-α) blockade improves natural killer cell (NK) activation, hypertension, and mitochondrial oxidative stress in a preclinical rat model of preeclampsia[J]. Hypertens Pregnancy, 2020, 39(4):399-404. doi: 10.1080/10641955.2020.1793999.
doi: 10.1080/10641955.2020.1793999 |
[24] |
Chau K, Bobek G, Xu B, et al. Effect of placental growth factor in models of experimental pre-eclampsia and trophoblast invasion[J]. Clin Exp Pharmacol Physiol, 2020, 47(1):49-59. doi: 10.1111/1440-1681.13169.
doi: 10.1111/1440-1681.13169 |
[25] |
Sánchez-Aranguren LC, Prada CE, Riaño-Medina CE, et al. Endothelial dysfunction and preeclampsia: role of oxidative stress[J]. Front Physiol, 2014, 5:372. doi: 10.3389/fphys.2014.00372.
doi: 10.3389/fphys.2014.00372 pmid: 25346691 |
[26] |
Lockwood CJ, Yen CF, Basar M, et al. Preeclampsia-related inflammatory cytokines regulate interleukin-6 expression in human decidual cells[J]. Am J Pathol, 2008, 172(6):1571-1579. doi: 10.2353/ajpath.2008.070629.
doi: 10.2353/ajpath.2008.070629 pmid: 18467705 |
[27] |
Cubro H, Kashyap S, Nath MC, et al. The Role of Interleukin-10 in the Pathophysiology of Preeclampsia[J]. Curr Hypertens Rep, 2018, 20(4):36. doi: 10.1007/s11906-018-0833-7.
doi: 10.1007/s11906-018-0833-7 |
[28] |
Sljivancanin Jakovljevic T, Kontic-Vucinic O, Nikolic N, et al. Glutathione-S-transferase M1 polymorphism and pro-inflammatory cytokines tumour necrosis factor-α and interleukin-1β are associated with preeclampsia in Serbian women[J]. Am J Reprod Immunol, 2019, 81(5):e13105. doi: 10.1111/aji.13105.
doi: 10.1111/aji.13105 |
[29] |
Nath MC, Cubro H, McCormick DJ, et al. Preeclamptic Women Have Decreased Circulating IL-10 (Interleukin-10) Values at the Time of Preeclampsia Diagnosis: Systematic Review and Meta-Analysis[J]. Hypertension, 2020, 76(6):1817-1827. doi: 10.1161/HYPERTENSIONAHA.120.15870.
doi: 10.1161/HYPERTENSIONAHA.120.15870 |
[30] |
Wu LY, He YL, Zhu LL. Possible Role of PHD Inhibitors as Hypoxia-Mimicking Agents in the Maintenance of Neural Stem Cells′ Self-Renewal Properties[J]. Front Cell Dev Biol, 2018, 6:169. doi: 10.3389/fcell.2018.00169.
doi: 10.3389/fcell.2018.00169 |
[31] |
Zhao L, Ma R, Zhang L, et al. Inhibition of HIF-1a-mediated TLR4 activation decreases apoptosis and promotes angiogenesis of placental microvascular endothelial cells during severe pre-eclampsia pathogenesis[J]. Placenta, 2019, 83:8-16. doi: 10.1016/j.placenta.2019.06.375.
doi: 10.1016/j.placenta.2019.06.375 |
[32] |
Chiarello DI, Abad C, Rojas D, et al. Oxidative stress: Normal pregnancy versus preeclampsia[J]. Biochim Biophys Acta Mol Basis Dis, 2020, 1866(2):165354. doi: 10.1016/j.bbadis.2018.12.005.
doi: 10.1016/j.bbadis.2018.12.005 |
[33] |
Mannaerts D, Faes E, Gielis J, et al. Oxidative stress and endothelial function in normal pregnancy versus pre-eclampsia, a combined longitudinal and case control study[J]. BMC Pregnancy Childbirth, 2018, 18(1):60. doi: 10.1186/s12884-018-1685-5.
doi: 10.1186/s12884-018-1685-5 |
[34] |
Taysi S, Tascan AS, Ugur MG, et al. Radicals, Oxidative/Nitrosative Stress and Preeclampsia[J]. Mini Rev Med Chem, 2019, 19(3):178-193. doi: 10.2174/1389557518666181015151350.
doi: 10.2174/1389557518666181015151350 |
[35] |
国林林, 赵慧栋, 胡海燕. 氧化应激对胎盘生命的影响[J]. 国际妇产科学杂志, 2019, 46(2):185-188. doi: 10.3969/j.issn.1674-1870.2019.02.017.
doi: 10.3969/j.issn.1674-1870.2019.02.017 |
[36] |
Vaka VR, McMaster KM, Cunningham MW Jr, et al. Role of Mitochondrial Dysfunction and Reactive Oxygen Species in Mediating Hypertension in the Reduced Uterine Perfusion Pressure Rat Model of Preeclampsia[J]. Hypertension, 2018, 72(3):703-711. doi: 10.1161/HYPERTENSIONAHA.118.11290.
doi: 10.1161/HYPERTENSIONAHA.118.11290 |
[37] |
Lumbers ER, Delforce SJ, Arthurs AL, et al. Causes and Consequences of the Dysregulated Maternal Renin-Angiotensin System in Preeclampsia[J]. Front Endocrinol(Lausanne), 2019, 10:563. doi: 10.3389/fendo.2019.00563.
doi: 10.3389/fendo.2019.00563 |
[38] |
Gant NF, Daley GL, Chand S, et al. A study of angiotensin II pressor response throughout primigravid pregnancy[J]. J Clin Invest, 1973, 52(11):2682-2689. doi: 10.1172/JCI107462.
doi: 10.1172/JCI107462 pmid: 4355997 |
[39] |
Wang P, Zhang S, Ren J, et al. The inhibitory effect of BKCa channels induced by autoantibodies against angiotensin II type 1 receptor is independent of AT1R[J]. Acta Biochim Biophys Sin(Shanghai), 2018, 50(6):560-566. doi: 10.1093/abbs/gmy038.
doi: 10.1093/abbs/gmy038 |
[40] |
Campbell N, LaMarca B, Cunningham MW Jr. The Role of Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor (AT1-AA) in Pathophysiology of Preeclampsia[J]. Curr Pharm Biotechnol, 2018, 19(10):781-785. doi: 10.2174/1389201019666180925121254.
doi: 10.2174/1389201019666180925121254 |
[1] | 马玲, 李亚西, 赵敏, 王静, 李红丽. 细胞凋亡与不良妊娠结局关系的研究进展[J]. 国际妇产科学杂志, 2025, 52(2): 121-126. |
[2] | 侯春艳, 杜秀萍, 王红红, 侯岳洋. 高迁移率族蛋白A2在胎儿生长受限发病机制中的研究进展[J]. 国际妇产科学杂志, 2025, 52(2): 127-131. |
[3] | 杨洋, 马媛, 陈宥艺, 赵静, 马文娟. 重度子痫前期患者血清外泌体对人正常蜕膜免疫细胞功能的影响[J]. 国际妇产科学杂志, 2025, 52(2): 143-152. |
[4] | 殷婷, 丛慧芳. 子宫内膜异位症与痛觉敏化的免疫学研究进展[J]. 国际妇产科学杂志, 2025, 52(2): 206-210. |
[5] | 王晶, 王永红. 蜕膜自然杀伤细胞在子痫前期发病机制中的研究进展[J]. 国际妇产科学杂志, 2025, 52(1): 88-93. |
[6] | 张雯, 刘慧强. SOCS1与外泌体微小RNA在子痫前期发病机制中的作用[J]. 国际妇产科学杂志, 2025, 52(1): 94-98. |
[7] | 王一丹, 王永红. 转化生长因子-β超家族在子痫前期发病机制中的作用[J]. 国际妇产科学杂志, 2025, 52(1): 99-104. |
[8] | 樊博扬, 胡丽燕. 双胎妊娠合并子痫前期发病机制及预测方法研究进展[J]. 国际妇产科学杂志, 2024, 51(6): 611-615. |
[9] | 邓玲玲, 伍绍文, 张为远. 小剂量阿司匹林在子痫前期预防中的研究进展[J]. 国际妇产科学杂志, 2024, 51(5): 515-518. |
[10] | 张琦, 王新, 任毅, 刘超, 高慧婕. SLRPs在胎盘发育及妊娠相关疾病中的研究进展[J]. 国际妇产科学杂志, 2024, 51(5): 525-530. |
[11] | 任毅, 胡玉莲, 王新, 张琦, 刘超, 高慧婕. 子痫前期的中药临床应用与现代药理学进展[J]. 国际妇产科学杂志, 2024, 51(4): 442-447. |
[12] | 赵丽霞, 王小青. 硫酸镁在子痫前期治疗中的争议及其不良反应[J]. 国际妇产科学杂志, 2024, 51(4): 448-452. |
[13] | 吴志韦, 林雪燕, 张雪芹, 杨梅琳. 子痫前期预防、预测的现状与关注焦点[J]. 国际妇产科学杂志, 2024, 51(3): 312-316. |
[14] | 张春双, 董晓真, 周昌荣, 王懿珊, 栗河舟. 宫内治疗胎儿胸腔积液合并水肿并发镜像综合征一例[J]. 国际妇产科学杂志, 2024, 51(3): 357-360. |
[15] | 彭兰, 柏婷, 周丽屏, 虞燕霞. 生物节律与子痫前期的相关性[J]. 国际妇产科学杂志, 2024, 51(2): 157-160. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||